Piper Sandler Reiterates Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 66.7%

Neg 0% Neu 0% Pos 66.7%

Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $41 to $42.